---
title: Help slow Parkinson disease progression
nct_id: NCT04888364
status: RECRUITING
sponsor: Institut National de la Santé Et de la Recherche Médicale, France
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT04888364"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04888364"
last_fetched: "2026-05-10T14:03:00.316Z"
source: "Parkinson's Pathways (curated)"
---
# Help slow Parkinson disease progression

**Goal (in five words):** Help slow Parkinson disease progression

**Official Title:** Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)

**Trial ID:** [NCT04888364](https://clinicaltrials.gov/study/NCT04888364)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Target Enrollment:** 30000 participants
- **Start Date:** 2021-06-16
- **Completion Date:** 2028-06-30
- **Conditions:** Parkinson Disease

## Summary For Families

Goal: Gather long-term clinical, genetic, imaging, and biological data across France to better understand how Parkinson's and related parkinsonian disorders begin, progress, and vary between people, and to identify early risk markers. Approach: People join an observational cohort with regular clinical exams and optional biosamples like blood and skin biopsy plus imaging when available, so researchers can link symptoms to biological and genetic clues; no experimental drug is given and usual treatments such as levodopa are continued as needed. Eligibility: Open to anyone age 10 and up who is covered by French social security and who has Parkinson's, another parkinsonian syndrome, or is at increased risk (for example a relative of a patient, a known PD gene carrier, or someone with idiopathic REM sleep behavior disorder), provided they can give informed consent and are not under legal protection.

## Eligibility

- **Minimum age:** 10 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of Parkinson's disease according to UK PD brain bak criteria
* OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom
* OR Subjects at risk of PD defined as :

No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015)

AND for all participants

* Affiliated to social security
* Age \> 10 years

Exclusion Criteria:

* Subject under legal protection
* Subject who do not consent to the research
* for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment
```

## Locations (1)

- Centre 01 Paris, Paris, France _(48.8534, 2.3488)_
  - Jean Christophe MD Corvol, Pr — (CONTACT) — 33 1 42 16 57 66 — jean-christophe.corvol@aphp.fr
  - Jean Christophe MD Corvol, Pr — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Jean Christophe MD CORVOL, PU-PH — (CONTACT) — 33 1 42 16 57 66 — jean-christophe.corvol@aphp.fr

---

*Canonical: https://parkinsonspathways.com/trial/NCT04888364*  
*HTML version: https://parkinsonspathways.com/trial/NCT04888364*  
*Source data: https://clinicaltrials.gov/study/NCT04888364*